×

Rich Pharmaceuticals Appoints Dr. Chieanchuang Kalayanamitr to Medical Advisory Board

BEVERLY HILLS, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company") is pleased to announce the appointment of Dr. Chieanchuang Kalayanamitr to the Company's Medical Advisory Board.

Dr. Kalayanamitr is a distinguished governmental advisor, member of numerous boards of directors and a University lecturer. Dr. Kalayanamitr received his Ph.D in Systems Management Sciences from Greenwich University and completed his graduate studies in environmental engineering from the University of North Carolina in Chapel Hill, North Carolina. Dr. Kalayanamitr advises the Government of Thailand and the Prime Ministers office on a variety of matters. Dr. Kalayanamitr is also on the board of directors and has consulted to companies including ENERCEL (homeopathic medicine), PSCC CO (diesel gas technology), Stern, Steward Thailand (management consulting) and PC&M/Project Control and Management Corp. (engineering consulting). Dr. Kalayanamitr has joined the Medical Advisory Board to assist the Company with establishing the protocols for the treatment of neurological indications and introductions to clinical sites and industry experts.

"We are honored to have Dr. Kalayanamitr join our Medical Advisory Board," said Ben Chang, Chief Executive Officer of the Company. "We will value his guidance in our planned clinical trials."

About Rich Pharmaceuticals:

Rich Pharmaceuticals, Inc. (OTCQB:RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate which is known as RP-323 (renamed from PD-616) is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.

Notice Regarding Forward-Looking Statements:

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

CONTACT: Ben Chang, CEO 9595 Wilshire Blvd., Suite 900 Beverly Hills, CA 90212 424-230-7001 EXT 105Source:Rich Pharmaceuticals, Inc.